Last reviewed · How we verify
Amino acid peritoneal dialysis solution
The Amino Acid Peritoneal Dialysis Solution, marketed by The People's Hospital of Gaozhou, holds a niche position in the peritoneal dialysis market. The key composition patent, set to expire in 2028, provides a significant barrier to entry for potential competitors. However, the lack of revenue data and key trial results poses a primary risk, making it difficult to assess the product's commercial viability and clinical efficacy.
At a glance
| Generic name | Amino acid peritoneal dialysis solution |
|---|---|
| Sponsor | The People's Hospital of Gaozhou |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Amino Acid (15) Peritoneal Dialysis Solution for Nutritional Improvement in Peritoneal Dialysis Patients (PHASE4)
- Clinical Study of the Use of Amino Acid Peritoneal Dialysate in Diabetic Patients (NA)
- Exploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis Solution (PHASE4)
- Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition. (PHASE4)
- Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease (PHASE3)
- The Safety and Tolerability of Intra-abdominal t-PA and DNase on Peritonitis in Peritoneal Dialysis Patients (PHASE1)
- Vancomycin Pharmacokinetics in Patients on Peritoneal Dialysis (PHASE1)
- Iplasma IL6, Procalcitonin and VEGF and Dialysate Level in CAPD Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: